The efficiency of tumor cell purging using immunomagnetic CD34+ cell separation systems

Bone Marrow Transplantation

Volumn 19, Issue 12, 1997, Pages 1239-1246

  Roots Weiss A ^a   Papadimitriou, C ^a   Serve, H ^a   Hoppe, B ^a   Koenigsmann, M ^a   Reufi, B ^a   Oberberg, D ^a   Thiel, E ^a   Berdel, W E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Breast cancer cells; CD34+ hematopoietic cells; Cloning assay; Immunomagnetic separation; Peripheral blood mononuclear cells; Tumor cell purging

Indexed keywords

AGAR; CD34 ANTIGEN; IMMUNOGLOBULIN G1; METHYLCELLULOSE; MICROSPHERE; MONOCLONAL ANTIBODY; PARAPROTEIN;

ARTICLE; BONE MARROW CELL; BONE MARROW PURGING; CELL CLONING; CELL SEPARATION; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKAPHERESIS; MAGNETIC FIELD; MONONUCLEAR CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; SOLID TUMOR; TECHNIQUE; TUMOR CELL;

EID: 0030753237     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700812     Document Type: Article

References (39)

1. Armitage JO, Antman KH (eds). High-Dose Cancer Therapy. Williams and Wilkins: Baltimore, USA, 1995.
2. Williams SF, Bitran JD, Richards JM et al. Peripheral blood-derived stem cell collections for use in autologous transplantation after high-dose chemotherapy: an alternative approach. Bone Marrow Transplant 1990; 5: 129-133.
3. Zander AR, Lyding J, Bielack S. Transplantation with blood stem cells. Blood Cells 1991; 17: 301-309.
4. To LB, Roberts MM, Haylock DN et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Morrow Transplant 1992; 9: 277-284.
5. Henon PR, Liang H, Beck-Wirth G et al. Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant 1992; 9: 285-291.
6. Sheridan WP, Begley CG, Juttner CA et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-644.
7. Beyer J, Schwella N, Zinsem J et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol 1995; 13: 1328-1335.
8. Ross AA, Cooper BW, Lazarus HM et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82: 2605-2610.
9. Moss TJ, Cairo M, Santana VM et al. Clonogenicity of circulating neuroblastoma cells: implications regarding peripheral blood stem cell transplantation. Blood 1994; 83: 3085-3089.
10. Sharp JG, Kessinger A, Vaughan WP et al. Detection and clinical significance of minimal tumor cell contamination of peripheral stem cell harvests. Int J Cell Clon 1992; 10 (Suppl. 1): 92-94.
11. Moss TJ, Ross AA. The risk of tumor cell contamination in peripheral blood stem cell collections. J Hematother 1992; 1: 225-232.
12. Mattano LA, Moss TJ, Emerson SG. Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase-polymerase chain reaction. Cancer Res 1992; 52: 4701-1705.
13. Negrin RS. Use of the polymerase chain reaction for the detection of tumor cell involvement of bone marrow and peripheral blood: implications for purging. J Hematother 1992; 1: 361-368.
14. Sanders DG, Wiley FM, Moss TJ. Serial immunocytologic analysis of blood for tumor cells in two patients with neuroblastoma. Cancer 1991; 67: 1423-1427.
15. Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 1993; 341: 85-86.
16. Deisseroth AB, Zu Z, Claxton D et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068-3076.
17. Brugger W, Bross KJ, Glatt M et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636-640.
18. Dietzfelbinger HF, Kühn D, Zafferani M et al. Removal of breast cancer cells from bone marrow by in vitro purging with ether lipids and cryopreservation. Cancer Res 1993; 53: 3747-3751.
19. Shpall EJ, Jones RB, Bast RC Jr et al. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase 1 trial. J Clin Oncol 1991; 9: 85-93.
20. Passos-Coelho J, Ross AA, Davis JM et al. Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperoxycyclophosphamide. Cancer Res 1994; 54: 2366-2371.
21. Myklebust AT, Godal A, Juell S et al. Comparison of two antibody-based methods for elimination of breast cancer cells from human bone marrow. Cancer Res 1994; 54: 209-214.
22. Treleaven JG, Gibson FM, Ugelstad J et al. Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microspheres. Lancet 1984; I: 70-73.
23. Watt SM, Karhi K, Gatter K et al. Distribution and epitope analysis of the cell membrane glycoprotein (HPCA-1) associated with human hemopoietic progenitor cells. Leukemia 1987; 1: 417-426.
24. Hill BT, Whelan RDH, Hosking LK et al. The value of human tumor continuous cell lines for investigating aspects of the methodologies used for in vitro drug sensitivity testing. In: Salmon SE, Trent JM (eds). Human Tumor Cloning. Grune & Stratton: Orlando, 1984, pp 487-496.
25. Korfel A, von Marschall Z, Koenigsmann M et al. Macrophage inflammatory protein (MIP)-1α/stem cell inhibitor (SCI) does not affect clonal growth of human solid tumor cell lines in vitro. Int J Oncol 1994; 4: 353-357.
26. Papadimitriou CA, Roots A, Koenigsmann M et al. Immunomagnetic selection of CD34+ cells from fresh peripheral blood mononuclear cell preparations using two different separation techniques. J Hematother 1995; 4: 539-544.
27. Gorin NC, Aegerter P, Auvert B et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 1990; 75: 1606-1614.
28. Gribben JG, Freedman AS, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. New Enql J Med 1991; 325: 1525-1533.
29. Freedman VH, Shin S. Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell 1974; 3: 355-359.
30. Gross JL, Behrens DL, Mullins DE et al. Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrate. Cancer Res 1988; 48: 291-296.
31. Hardwick RA, Kulcinski D, Mansour V et al. Design of large-scale separation systems for positive and negative immunomagnetic selection of cells using superparamagnetic microspheres. J Hematother 1992; 1: 379-386.
32. Verbeek W, Pies A, Humpe A et al. Mobilization of CD34-positive tumour cells in a patient with testicular mixed germ cell tumour. Br J Haematol 1995; 90: 947-950.
33. Köhler G, Brugger W, Schaefer HE, Kanz L. CD34 antigen expression in malignant solid tumors and lymphomas: a immunhistochemical study. Onkologie 1994; 17 (Suppl. 2) (Abstr.) 78.
34. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12: 28-36.
35. + cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin. Blood 1994; 84: 1421-1426.
36. + cells. Int J Oncol 1996; 9: 1107-1112.
37. Vredenburgh J, Shpall EJ, Ross M et al. Immunopharmacologic bone marrow purging and high dose chemotherapy with autologous bone marrow support (ABMS) for patients with metastatic breast cancer. Proc Am Soc Clin Oncol 1992; 11 (Abstr.) 58.
38. Anderson IC, Shpall EJ, Leslie DS et al. Elimination of malignant clonogenic breast cancer cells from human bone marrow. Cancer Res 1989; 49: 4659-4664.
39. Berdel WE, Okamoto S, Reichert A et al. Studies on the role of ether lipids as purging agents in autologous bone marrow transplantation. In: Kabara JJ (ed). The Pharmacological Effects of Lipids III. The American Oil Chemists' Society, AOCS-Press: Champaign, IL, 1989, pp 338-360.